Akari Therapeutics (AKTX) Stock Analysis & Winston Score

Akari Therapeutics is a small clinical-stage biotechnology company focused on developing drugs to treat rare and serious inflammatory diseases. Its main drug candidate, nomacopan, targets conditions where the immune system attacks the body, including a rare eye disease called geographic atrophy and a blood disorder called hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The company does not yet sell any approved products. Akari earns no product revenue today and funds its operations through equity raises and grants, which is typical for early-stage biotech companies. It is headquartered in London with operations in the United States, and its entire value rests on whether its drug candidates succeed in clinical trials and win regulatory approval. The biggest risk is that clinical trials fail or take longer than expected, which could force the company to raise more money and dilute existing shareholders.